Achievements

First single-dose medicine to prevent the relapse of P. vivax approved by US FDA

Two rectal artesunate suppository products for pre-referral management of severe malaria approved

68 million courses of seasonal malaria chemoprevention delivered to countries in the Sahel in 2017

350 million treatments of Coartem® Dispersible delivered to over 50 countries

Pyramax® Granules added to the WHO's Model List of Essential Medicines for Children

100 million vials of Artesun® delivered to treat children with severe malaria

CANTAM study initiated

14 compounds in preclinical and clinical development

Over 230 Pathogen Boxes shipped

18,000 health-care workers trained to administer injectable artesunate for severe malaria

USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners

160 active partners in MMV's network, working to help defeat malaria

>90% of severe malaria cases now treated with injectable artesunate in preference to quinine

19 new malaria drug targets validated since 1999

MMV wins Open Data Innovation Award for work on the Malaria Box
Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

2 ACTs developed by DNDi and partners transitioned to MMV

More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots

Key landmarks for MMV-supported medicines

Key Achievements over MMV's first 15 years